TY - JOUR T1 - Blood Pressure and Risk of Atrial Fibrillation: A Mendelian Randomization Study JF - medRxiv DO - 10.1101/2020.07.26.20162339 SP - 2020.07.26.20162339 AU - Matthew C. Hyman AU - Michael G. Levin AU - Dipender Gill AU - Venexia M. Walker AU - Marios K. Georgakis AU - Neil Davies AU - Francis E. Marchlinski AU - Scott M. Damrauer Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/29/2020.07.26.20162339.abstract N2 - Importance Observational studies have shown an association between hypertension and atrial fibrillation (AF). Aggressive blood pressure management in patients with known AF reduces overall arrhythmia burden, but it remains unclear whether hypertension is causative for AF.Objective The primary objective of this study was to investigate the relationship between blood pressure and risk of AF using genetic proxies for blood pressure within a Mendelian randomization (MR) framework. We secondarily explored the relationship between genetically proxied use of anti-hypertensive drugs and risk of AF.Design Two-sample MR was performed using an inverse-variance weighted meta-analysis with weighted median MR and Egger intercept tests performed as sensitivity analyses. Genetic proxies for the anti-hypertensive drug classes were used to investigate the impact of these therapies on the risk of AF.Setting International Consortium of Blood Pressure, UK Biobank and Atrial Fibrillation Genetics Consortium.Participants Summary statistics for systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) were obtained from the International Consortium of Blood Pressure and the UK Biobank discovery analysis (>750,000 individuals of European ancestry).Summary statistics for AF were obtained from the 2018 Atrial Fibrillation Genetics Consortium multi-ethnic GWAS (>65,000 AF cases and >522,000 referents).Exposure Genetically predicted SBP, DBP and PP as quantified by risk scores.Main Outcome Odds ratio for AF per 10 mmHg increase in genetically proxied blood pressure.Results Ten mmHg increases in genetically proxied SBP, DBP or PP were associated with increased odds of AF (SBP: OR 1.17, 95% CI 1.11-1.22, p=1⨯ 10−11; DBP: OR 1.25, 95% CI 1.16-1.35, p=3⨯ 10−8; PP: OR 1.1, 95% CI 1.0-1.2, p=0.05). Ten mmHg decreases in SBP estimated by genetic proxies of anti-hypertensive medications showed calcium channel blockers (OR 0.66, 95% CI 0.57-0.76, p=8⨯ 10−9) and beta-blockers (OR 0.61, 95% CI 0.46-0.81, p=6⨯ 10−4) decreased the risk of AF.Conclusions and Relevance Blood pressure-increasing genetic variants were associated with increased risk of AF, consistent with a causal relationship between blood pressure and AF. These data support the concept that blood pressure reduction through pharmacologic intervention, and specifically calcium channel blockade or beta blockade could reduce the risk of AF.Competing Interest StatementAll authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Gill is employed part-time by Novo Nordisk outside of the submitted work. Dr. Damrauer receives research support to his institution from RenalytixAI and personal consulting fees from Calico Labs, both outside the current work. No other disclosures were reported.Funding StatementDrs. Hyman and Marchlinski are supported by the Winkelman Family Fund in Cardiovascular Innovation. Dr. Gill is supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London. Dr Walker is supported by the Medical Research Council Integrative Epidemiology Unit. The unit is supported by the UK Medical Research Council and University of Bristol (MC_UU_00011/4 and MC_UU_00011/1). Dr. Damrauer is supported by the Department of Veterans Affairs (IK2-CX001780). This publication does not represent the views of the Department of Veterans Affairs or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Initial IRB approval was obtained through AFGen, International Consortium for Blood Pressure, UK BiobankAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this study were obtained from publicly available sources. https://grasp.nhlbi.nih.gov/FullResults.aspx http://www.kp4cd.org/datasets/v2f AbbreviationsAFatrial fibrillationBBbeta-blockerCCBcalcium channel blockerDBPdiastolic blood pressureeQTLExpression quantitative trait lociLDlinkage disequilibriumMRMendelian randomizationPPPulse pressureSBPsystolic blood pressure ER -